European PRRSpective 2023 session 2 Controlling farm breakdowns
Dr DiPietre analyses the economic impact of PRRS to the whole herd. He cautions that we need to re-evaluate how we measure these costs by looking closer at individual data and the impact of variation.
The aim of the study was to calculate the time to PRRSv-stability (TTS), the time-to-baseline-production (TTBP) and total losses in a European context.
The use of INGELVAC PRRS vaccines can significantly reduce lung lesions following challenge with heterologous isolates (86- 94% ORF5 nucleotide similarity) in the three-week-old pig respiratory challenge model.1 INGELVAC PRRS MLV demonstrated heterologous protection against challenge with current PRRSV lineage-1 RFLP 1-7-4 and 1-3-4 isolates.2 The objective of this study was to evaluate the efficacy of two commercially available PRRSV vaccines in a three-week-old pig respiratory challenge model, using a heterologous PRRSV lineage-1 RFLP 1-7-4 field strain that was isolated in 2016.
Despite the intensive vaccination programs applied in the field, erysipelas continues to be a costly global concern for the swine industry and public health 1,2,3. Post-farrowing vaccination is routinely applied to protect the breeding stock. However, there is a need to vaccinate growing pigs due to a lack of protection in the finishing period, and it is not uncommon to detect outbreaks in the field due to antibody waning 4,5. There is a need for further studies that aim at investigating other vaccination protocols that may increase protection against erysipelas under commercial conditions. Therefore, the specific objectives of this study were two-fold: 1) to study the seroconversion in sows and piglets between pre- and post-farrowing protocols against erysipelas over time; and 2) to describe the time-to-negative erysipelas protection between protocols.